A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier:
NCT00110305
First received: May 5, 2005
Last updated: August 21, 2013
Last verified: August 2013
Results First Received: April 26, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Human Immunodeficiency Virus Type 1
Interventions: Drug: TMC278 25 mg
Drug: TMC278 75 mg
Drug: TMC278 150 mg
Drug: Efavirenz
Drug: Non-nucleoside reverse transcriptase inhibitor (NRTIs)

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
TMC278 25 mg TMC278 25 mg once daily
TMC278 75 mg TMC278 75 mg once daily
TMC 150 mg TMC278 150 mg once daily
Efavirenz Efavirenz 600 mg once daily
Total Total of all reporting groups

Baseline Measures
    TMC278 25 mg     TMC278 75 mg     TMC 150 mg     Efavirenz     Total  
Number of Participants  
[units: participants]
  93     95     91     89     368  
Age  
[units: participants]
         
<=18 years     0     0     0     0     0  
Between 18 and 65 years     92     95     89     89     365  
>=65 years     1     0     2     0     3  
Age  
[units: years]
Mean ± Standard Deviation
  36.7  ± 8.9     36.3  ± 8.3     35.9  ± 9.7     35.4  ± 8.1     36.1  ± 8.75  
Gender  
[units: participants]
         
Female     28     31     33     29     121  
Male     65     64     58     60     247  
Region Enroll  
[units: participants]
         
Asia, South Africa and Uganda     32     32     31     29     124  
Europe, USA and Russia     33     33     32     32     130  
Latin America     28     30     28     28     114  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Virologic Response at Week 48 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm   [ Time Frame: Week 48 ]

2.  Secondary:   Number of Participants With Virologic Response at Week 96 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm   [ Time Frame: Week 96 ]

3.  Secondary:   Number of Participants With Virologic Response at Week 96 (Viral Load Less Than 50 Copies Per mL) - Snapshot Analysis   [ Time Frame: Week 96 ]

4.  Secondary:   Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm   [ Time Frame: Week 240 ]

5.  Secondary:   Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 50 Copies Per mL) - Snapshot Analysis   [ Time Frame: Week 240 ]

6.  Secondary:   Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 400 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm   [ Time Frame: Week 240 ]

7.  Secondary:   Change From Baseline in CD4+ Cell Count (Absolute) at Week 96   [ Time Frame: Baseline (Day 1 of Week 0) to Week 96 ]

8.  Secondary:   Change From Baseline in CD4+ Cell Count (Relative) at Week 96   [ Time Frame: Baseline (Day 1 of Week 0) to Week 96 ]

9.  Secondary:   Change From Baseline in CD4+ Cell Count (Absolute) at Week 240   [ Time Frame: Baseline (Day 1 of Week 0) to Week 240 ]

10.  Secondary:   Change From Baseline in CD4+ Cell Count (Relative) at Week 240   [ Time Frame: Baseline (Day 1 of week 0) to Week 240 ]

11.  Secondary:   Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure   [ Time Frame: Week 240 ]

12.  Secondary:   Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours (AUC24h) for TMC278   [ Time Frame: Up to Week 96 ]

13.  Secondary:   Trough Plasma Concentration (Ctrough) for TMC278   [ Time Frame: Up to Week 96 ]

14.  Secondary:   Number of Participants With Virologic Response (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm, by Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours (AUC24h) Quartiles   [ Time Frame: Up to Week 96 ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Director
Organization: Janssen-Virco BE
phone: 32 14 641418 ext NA


No publications provided by Tibotec Pharmaceuticals, Ireland

Publications automatically indexed to this study:

Responsible Party: Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier: NCT00110305     History of Changes
Obsolete Identifiers: NCT00980837
Other Study ID Numbers: CR006760, TMC278-C204, R278474-C204
Study First Received: May 5, 2005
Results First Received: April 26, 2013
Last Updated: August 21, 2013
Health Authority: United States: Food and Drug Administration